Related Experiment Video

Updated: Jun 12, 2026

Using En Face Immunofluorescence Staining to Observe Vascular Endothelial Cells Directly
06:09

Using En Face Immunofluorescence Staining to Observe Vascular Endothelial Cells Directly

Published on: August 20, 2019

[Endothelin in cardiovascular diseases pathophysiology]

Łukasz Dobrek1, Piotr Thor

  • 1Katedra Patofizjologii Collegium Medicum Uniwersytetu Jagiellońskiego. lukaszd@mp.pl

Polski Merkuriusz Lekarski : Organ Polskiego Towarzystwa Lekarskiego
|May 25, 2010
PubMed

Insights

Endothelin-1 (ET-1), a potent polypeptide, plays a key role in cardiovascular diseases like arteriosclerosis and heart failure. Blocking ET-1 offers a promising pharmacotherapy approach targeting neurohormonal pathways.

Area of Science:

  • Biochemistry
  • Physiology
  • Pharmacology

Context:

  • Endothelin-1 (ET-1) is a polypeptide with diverse physiological effects.
  • Experimental and clinical studies highlight ET-1's role in cardiovascular pathophysiology.

Purpose:

  • To describe the biochemical properties of ET-1.
  • To elucidate the pathophysiological role of ET-1 in cardiovascular diseases.

Summary:

  • ET-1 is implicated in arteriosclerosis, heart failure, pulmonary hypertension, and renal failure.
  • ET-1 also plays a role in certain neoplastic conditions.
  • Targeting ET-1 via blockade is a potential pharmacotherapeutic strategy.

Impact:

  • Understanding ET-1's role informs therapeutic strategies for cardiovascular and neoplastic diseases.
  • ET-1 blockade represents a novel approach in pharmacotherapy targeting neurohormonal mechanisms.

More Related Videos

In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time09:19

In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time

Published on: May 24, 2020

Ultrasound Assessment of Endothelial Function: A Technical Guideline of the Flow-mediated Dilation Test06:35

Ultrasound Assessment of Endothelial Function: A Technical Guideline of the Flow-mediated Dilation Test

Published on: April 27, 2016

Related Concept Videos

Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...